Nutritional Biomarkers for Predicting Pancreatic Beta Cell Failure in Central Obesity

Miftakh Nur Rahman, Ajeng Diantini, Miswar Fattah, Melisa Intan Barliana

Abstract


BACKGROUND: There is a continuous rise in the prevalence of central obesity and become a pressing health problem in the world. Central obesity followed by many metabolic disorders especially Type 2 Diabetes Mellitus (T2DM). The pathogenesis started from overnutrition signal that force pancreatic beta cells to produce a large number of insulin. Low-grade chronic inflammation that occurred also affects the organs sensitivity against insulin and caused beta cells to compensated this situation and at the end become exhausted and loss its function.

CONTENT: Along compensation mechanism, certain nutrients were support the beta cells to maintain their mass and function to produce insulin. Short chain fatty acids (SCFAs) are gut microbiota fermentation product that act as nutrient and give an advantage to the proliferation and survivability of the beta cells. Zinc (Zn) also plays an important role in every step of insulin production. Moreover, these nutrients protecting pancreas against inflammation and oxidative stress through certain mechanism. Most of patients with central obesity are unaware of the presence of this disturbance at early stage. Whereas, at molecular level there is a magnitude of SCFAs and Zn level in the blood that would become an early signal and predict the damage of beta cells.

SUMMARY: Quantification of these two nutrients in the blood expected to provide an early warning tool to maintain insulin adequacy and predict the possibility of beta cell failure in central obesity with promising performance.

KEYWORDS: central obesity, T2DM, SCFAs, Zinc, beta cell failure

 


Full Text:

PDF

References


World Health Organization [Internet]. Obesity and overweight [cited 2020 Nov 6]. Available from: https://www.who.int/.

James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001; 9 (Suppl 4): 228S-33S, CrossRef.

Nuttall FQ. Body mass index: obesity, BMI, and health: a critical review. Nutr Today. 2015; 50: 117-28, CrossRef.

Olinto MTA, Theodoro H, Canuto R. Epidemiology of abdominal obesity. In: Gordeladze JO, editor. Adiposity - Epidemiol Treat Modalities. London: IntechOpen; 2017, CrossRef.

Wong MCS, Huang J, Wang J, Chan PSF, Lok V, Chen X, et al. Global, regional and time-trend prevalence of central obesity: a systematic review and meta-analysis of 13.2 million subjects. Eur J Epidemiol. 2020; 35: 673-83, CrossRef.

Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci AMS. 2015; 11: 463-82, CrossRef.

Ohnishi H, Saitoh S, Takagi S, Katoh N, Chiba Y, Akasaka H, et al. Incidence of type 2 diabetes in individuals with central obesity in a rural Japanese population: the Tanno and Sobetsu Study. Diabetes Care. 2006; 29: 1128-9, CrossRef.

Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. J Diabetes Investig. 2014; 5: 507-12, CrossRef.

Wang C, Liu Z, Zhang P, Ma X, Che K, Wang Y, et al. The differences in homeostasis model assessment values in type 2 diabetic patients with different lengths of history of diabetes. Arch Endocrinol Metab. 2019; 63: 222-7, CrossRef.

Song I, Roels S, Martens GA, Bouwens L. Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds. PloS One. 2017; 12: e0186480, CrossRef.

Song Y, Manson JE, Tinker L, Howard BV, Kuller LH, Nathan L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment (HOMA) and risk of diabetes in a multiethnic cohort of women: the women’s health initiative observational study. Diabetes Care. 2007; 30: 1747-52, CrossRef.

Saisho Y. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015; 6: 109-24, CrossRef.

Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci Rep. 2019; 9: 12515, CrossRef.

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet Lond Engl. 2004; 363: 157-63, CrossRef.

Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities – Mechanisms of association. Arq Bras Endocrinol Metabol. 2014; 58: 600-9, CrossRef.

Guebre-Egziabher F, Alix PM, Koppe L, Pelletier CC, Kalbacher E, Fouque D, et al. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function. Biochimie. 2013; 95: 1971-9, CrossRef.

Tulloch-Reid MK, Hanson RL, Sebring NG, Reynolds JC, Premkumar A, Genovese DJ, et al. Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in african americans. Obes Res. 2004; 12: 1352-9, CrossRef.

International Obesity Task Force. The Asia Pacific Perspective: Redifining Obesity and Its Treatment. Sydney: Health Communications Australia; 2000, article.

Item F, Konrad D. Visceral fat and metabolic inflammation: the portal theory revisited. Obes Rev Off J Int Assoc Study Obes. 2012;13 (Suppl 2): 30-9, CrossRef.

Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016; 125: 259-66, CrossRef.

Ye J, McGuinness OP. Inflammation during obesity is not all bad: evidence from animal and human studies. Am J Physiol Endocrinol Metab. 2013; 304: E466-77, CrossRef.

Meiliana A, Wijaya A. Metaflammation, NLRP3 Inflammasome, Obesity and Metabolic Disease. Indones Biomed J. 2011; 3: 168-84, CrossRef.

Brereton MF, Rohm M, Ashcroft FM. β-Cell dysfunction in diabetes: a crisis of identity? Diabetes Obes Metab. 2016; 18 (Suppl 1): 102-9, CrossRef.

Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013; 4: 37, CrossRef.

Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012; 148: 1160-71, CrossRef.

Butler AE, Dhawan S. β-Cell identity in type 2 diabetes: lost or found? Diabetes. 2015; 64: 2698-700, CrossRef.

Templeman NM, Skovsø S, Page MM, Lim GE, Johnson JD. A causal role for hyperinsulinemia in obesity. J Endocrinol. 2017; 232: R173-83, CrossRef.

Indonesian Diabetes Association. Guidelines on the management and prevention of prediabetes. Acta Medica Indones. 2014; 46: 348-59, article.

Kim CH. Microbiota or short-chain fatty acids: which regulates diabetes? Cell Mol Immunol. 2018; 15: 88-91, CrossRef.

Liu JL, Segovia I, Yuan X-L, Gao Z. Controversial roles of gut microbiota-derived short-chain fatty acids (SCFAs) on pancreatic β-Cell growth and insulin secretion. Int J Mol Sci. 2020; 21: 910, CrossRef.

Priyadarshini M, Wicksteed B, Schiltz GE, Gilchrist A, Layden BT. SCFA receptors in pancreatic β cells: novel diabetes targets? Trends Endocrinol Metab. 2016; 27: 653-64, CrossRef.

Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016; 165: 1332-45, CrossRef.

Ding R, Goh WR, Wu R, Yue X, Luo X, Khine WWT, et al. Revisit gut microbiota and its impact on human health and disease. J Food Drug Anal. 2019; 27: 623-31, CrossRef.

Heimann E, Nyman M, Degerman E. Propionic acid and butyric acid inhibit lipolysis and de novo lipogenesis and increase insulin-stimulated glucose uptake in primary rat adipocytes. Adipocyte. 2014; 4: 81-8, CrossRef.

Li X, Shimizu Y, Kimura I. Gut microbial metabolite short-chain fatty acids and obesity. Biosci Microbiota Food Health. 2017; 36: 135-40, CrossRef.

den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013; 54: 2325-40, CrossRef.

Wei JW, Huang K, Yang C, Kang CS. Non-coding RNAs as regulators in epigenetics. Oncol Rep. 2017; 37: 3-9, CrossRef.

Fellows R, Denizot J, Stellato C, Cuomo A, Jain P, Stoyanova E, et al. Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases. Nat Commun. 2018; 9: 105, CrossRef.

Pingitore A, Chambers ES, Hill T, Maldonado IR, Liu B, Bewick G, et al. The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes Metab. 2017; 19: 257-65, CrossRef.

Bilotta AJ, Cong Y. Gut microbiota metabolite regulation of host defenses at mucosal surfaces: implication in precision medicine. Precis Clin Med. 2019; 2: 110-9, CrossRef.

Villa SR, Priyadarshini M, Fuller MH, Bhardwaj T, Brodsky MR, Angueira AR, et al. Loss of free fatty acid receptor 2 leads to impaired islet mass and beta cell survival. Sci Rep. 2016; 6: 28159, CrossRef.

Li M, van Esch BCAM, Wagenaar GTM, Garssen J, Folkerts G, Henricks PAJ. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol. 2018; 831: 52-9,

Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009; 27: 485-517, CrossRef.

Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA. 2014; 111: 2247-52, CrossRef.

Asarat M, Apostolopoulos V, Vasiljevic T, Donkor O. Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells in vitro. Immunol Invest. 2016; 45: 205-22, CrossRef.

Chambers ES, Preston T, Frost G, Morrison DJ. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep. 2018; 7: 198-206, CrossRef.

Meyer JA, Spence DM. A perspective on the role of metals in diabetes: past findings and possible future directions. Metallomics. 2009; 1: 32-41, CrossRef.

Rutter GA, Chabosseau P, Bellomo EA, Maret W, Mitchell RK, Hodson DJ, et al. Intracellular zinc in insulin secretion and action: a determinant of diabetes risk? Proc Nutr Soc. 2016; 75: 61-72, CrossRef.

Huang Q, Du J, Merriman C, Gong Z. Genetic, functional, and immunological study of ZnT8 in diabetes. Int J Endocrinol. 2019; 2019: 1524905, CrossRef.

Giacconi R, Malavolta M, Chiodi L, Boccoli G, Costarelli L, Bonfigli AR, et al. ZnT8 Arg325Trp polymorphism influences zinc transporter expression and cytokine production in PBMCs from patients with diabetes. Diabetes Res Clin Pract. 2018; 144: 102-10, CrossRef.

Foster M, Samman S. Zinc and regulation of inflammatory cytokines: implications for cardiometabolic disease. Nutrients. 2012; 4: 676-94, CrossRef.

Martins LM, Oliveira ARS de, Cruz KJC, Nogueira N do N, Marreiro D do N, Araújo CGB de, et al. Influence of cortisol on zinc metabolism in morbidly obese women. Nutr Hosp. 2014; 29: 57-63, CrossRef.

Donath MY, Størling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med Berl Ger. 2003; 81: 455-70, CrossRef.

Hoeger J, Simon TP, Doemming S, Thiele C, Marx G, Schuerholz T, et al. Alterations in zinc binding capacity, free zinc levels and total serum zinc in a porcine model of sepsis. Biometals Int J Role Met Ions Biol Biochem Med. 2015; 28: 693-700, CrossRef.

Rahman MN, Sukmawati IR, Puspitasari IM, Fattah M. Serum free zinc as a predictor for excessive function of pancreatic beta-cells in central-obese men. Indones Biomed J. 2019; 11: 262-6, CrossRef.




DOI: https://doi.org/10.18585/inabj.v13i1.1440

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute